earnings
confidence high
sentiment neutral
materiality 0.75
Merck Q1 revenue $14.5B (-9%), GAAP EPS $1.11; raises FY non-GAAP EPS guidance to $6.88-$7.00
Merck & Co., Inc.
2023-Q1 EPS reported
$1.11
revenue$14,487,000,000
- Q1 revenue $14.5B, down 9% YoY; excluding LAGEVRIO and FX, up 15%.
- GAAP EPS $1.11, Non-GAAP EPS $1.40; both down 35% YoY.
- KEYTRUDA sales $5.8B (+20%), GARDASIL sales $2.0B (+35% YoY).
- LAGEVRIO sales fell 88% to $392M; proposed Prometheus acquisition for $10.8B expected Q3 2023.
- FY2023 outlook raised: sales $57.7-$58.9B, Non-GAAP EPS $6.88-$7.00; GAAP EPS lowered to $5.85-$5.97 on Zetia settlement.